Literature DB >> 6248546

A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor.

A De Lean, J M Stadel, R J Lefkowitz.   

Abstract

The unique properties of agonist binding to the frog erythrocyte beta-adrenergic receptor include the existence of two affinity forms of the receptor. The proportion and relative affinity of these two states of the receptor for ligands varies with the intrinsic activity of the agonist and the presence of guanine nucleotides. The simplest model for hormone-receptor interactions which can explain and reproduce the experimental data involves the interaction of the receptor R with an additional membrane component X, leading to the agonist-promoted formation of a high affinity ternary complex HRX. Computer modeling of agonist binding data with a ternary complex model indicates that the model can fit the data with high accuracy under conditions where the ligand used is either a full or a partial agonist and where the system is altered by the addition of guanine nucleotide or after treatment with group-specific reagents, e.g. p-hydroxymercuribenzoate. The parameter estimates obtained indicate that the intrinsic activity of the agonist is correlated significantly with the affinity constant L of the component X for the binary complex HR. The major effect of adding guanine nucleotides is to destabilize the ternary complex HRX from which both the hormone H and the component X can dissociate. The modulatory role of nucleotides on the affinity of agonists for the receptor is consistent with the assumption that the component X is the guanine nucleotide binding site. The ternary complex model was also applied successfully to the turkey erythrocyte receptor system. The model provides a general scheme for the activation by agonists of adenylate cyclase-coupled receptor systems and also of other systems where the effector might be different.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248546

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  343 in total

Review 1.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Most central nervous system D2 dopamine receptors are coupled to their effectors by Go.

Authors:  M Jiang; K Spicher; G Boulay; Y Wang; L Birnbaumer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

3.  Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis.

Authors:  A Chen; Z G Gao; D Barak; B T Liang; K A Jacobson
Journal:  Biochem Biophys Res Commun       Date:  2001-06-15       Impact factor: 3.575

4.  Molecular dynamics investigation of primary photoinduced events in the activation of rhodopsin.

Authors:  Jan Saam; Emad Tajkhorshid; Shigehiko Hayashi; Klaus Schulten
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

5.  Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.

Authors:  M F Morton; E A Harper; I A Tavares; N P Shankley
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 6.  Role of G protein-coupled receptors in inflammation.

Authors:  Lei Sun; Richard D Ye
Journal:  Acta Pharmacol Sin       Date:  2012-02-27       Impact factor: 6.150

7.  Introduction of Robert J. Lefkowitz.

Authors:  Ralph Snyderman
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

8.  Delayed effects of spiperone on serotonin1A receptors in the dorsal hippocampus of rats.

Authors:  T Dennis; P Blier; C de Montigny
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

9.  Binding of agonists and antagonists to beta-adrenoceptors in rat vas deferens: relationship to functional response.

Authors:  J M May; P W Abel; K P Minneman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-12       Impact factor: 3.000

10.  (-)Tertatolol is a potent antagonist at pre- and postsynaptic serotonin 5-HT1A receptors in the rat brain.

Authors:  T Jolas; S Haj-Dahmane; L Lanfumey; C M Fattaccini; E J Kidd; J Adrien; H Gozlan; B Guardiola-Lemaitre; M Hamon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.